A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

This observational study is following patients treated with donanemab (a drug that removes amyloid plaques from the brain) for Alzheimer's disease in the real world — outside of a clinical trial — to compare outcomes with those who receive standard care, using electronic health records. **You may be eligible if...** - You have mild cognitive impairment (early memory problems) or mild-stage Alzheimer's disease - You have confirmed amyloid plaque buildup in your brain (shown by blood tests, PET scan, or spinal fluid analysis) - You scored at least 21 on the Telephone Interview for Cognitive Status (TICS) - You have a reliable study partner (family member or caregiver) who can be contacted every 6 months - Your electronic health records are available for research linkage **You may NOT be eligible if...** - You have had a prior stroke that significantly affects your daily functioning - You have another serious illness likely to affect your life expectancy or ability to complete the study - You require long-term institutional-level care - You do not have a study partner available Talk to your doctor to see if this trial is right for you.